Journals / Türk Nöroloji Dergisi / 2017 / Cilt: 23 - Sayı: 3

Amiselimod: A New Oral Agent in the Treatment of Multiple Sclerosis

Multipl Skleroz Tedavisinde Yeni Oral Ajan Amiselimod

Pages
148–149
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

EMEKLİ, A. S. (2022). Amiselimod: A New Oral Agent in the Treatment of Multiple Sclerosis. Türk Nöroloji Dergisi, Cilt: 23 - Sayı: 3, 148–149. https://ajindex.com/articles/636850

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Kappos L, Arnold DL, Bar-Or A, Camm J, Derfuss T, Kieseier BC, Sprenger T, Greenough K, Ni P, Harada T. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2016;15:1148-1159.